Barclays PLC Raises Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Barclays PLC boosted its position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 24.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,674 shares of the company’s stock after buying an additional 1,109 shares during the period. Barclays PLC’s holdings in ClearPoint Neuro were worth $64,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in shares of ClearPoint Neuro during the second quarter worth approximately $32,000. XTX Topco Ltd grew its holdings in shares of ClearPoint Neuro by 11.6% during the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock worth $70,000 after buying an additional 1,353 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of ClearPoint Neuro in the third quarter valued at about $123,000. Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter worth about $156,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in ClearPoint Neuro during the second quarter worth about $175,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Stock Up 0.4 %

NASDAQ CLPT opened at $17.85 on Friday. ClearPoint Neuro, Inc. has a 52 week low of $5.11 and a 52 week high of $19.00. The business’s fifty day simple moving average is $14.61 and its 200-day simple moving average is $12.09. The firm has a market cap of $492.30 million, a PE ratio of -25.87 and a beta of 1.01.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Thursday, November 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $8.12 million during the quarter, compared to analyst estimates of $8.07 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. During the same quarter in the previous year, the firm earned ($0.20) earnings per share. Research analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Lake Street Capital increased their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.